Foundation Medicine

Foundation Medicine, Inc.Founded in 2010 in Boston, US, Foundation Medicine, Inc. specializes in genomic profiling to assist in personalized cancer treatments.2 mn, and later secured an acquisition deal with F. Hoffmann-La Roche Ltd for USD 780 mn in April 2015.Foundation Medicine specializes in advanced genomic profiling solutions designed to enhance cancer care through a comprehensive understanding of the genomic mutations that drive cancer. The company's primary offerings include FoundationOne® CDx, FoundationOne® Liquid CDx, and FoundationOne® RNA. These products utilize next-generation sequencing to identify genomic alterations in solid tumors and circulating tumor DNA (ctDNA), enabling personalized treatment plans by matching patients with relevant targeted therapies, immunotherapies, and clinical trial options. The FoundationOne® CDx test analyzes formalin-fixed, paraffin-embedded (FFPE) tissue for mutations across 324 genes and genomic signatures, while FoundationOne® Liquid CDx and FoundationOne® RNA focus on plasma specimens and RNA fusions, respectively.41 mn. The company's revenue model is built on B2B transactions, where hospitals, oncology practices, and research institutions purchase genomic profiling tests for patient evaluation and drug development purposes.Foundation Medicine aims to enhance its product offerings and expand its market reach. The company is focused on developing new genomic profiling products, although specific release dates are not detailed. It plans to penetrate international markets, targeting regions in Europe and Asia by 2023. The recent acquisition by F.

1. Series B

   Sep 20, 2012

   Amount

   $43M

   Investors

   Locked

2. Series A

   Apr 18, 2012

   Amount

   $6.2M

   Investors

   Locked

3. Series A

   Oct 18, 2011

   Amount

   $8.5M

   Investors

   Locked

4. Series A

   Aug 23, 2011

   Amount

   $10M

   Investors

   Locked

5. Series A

   Apr 16, 2010

   Amount

   $25M

   Investors

   Locked